The co-develop liver cancer drug between Medigen and Oncolys BioPharma Inc.(Oncolys, Tokyo Stock Exchange #45880 ) , OBP-301, had signed a license agreement with Jiangsu Hengrui Medicine Co., Ltd. (Hengrui, Shanghai Stock Exchange #600276). In this exclusive agreement, Hengrui will have the right to China, Hong Kong, and Macau for the oncolytic virus OBP-301. Since Medigen and Oncolys “Strategic Alliances and License Agreement”, the profit generate from this agreement, will share between Oncolys and Medigen, two to one.
Reference announcement and reports:
1. Announcement from Oncolys (in Japanese)
2. Report from Central News Agency (in Chinese)
3. Report from Chinatimes.com (in Chinese)